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The purpose of this study is to characterize synovial ﬂuid- (SF-) derived exosomes of patients with gonarthrosis
comparing two methods of isolation and to investigate their immune regulatory properties. Extracellular vesicles (EVs)
have been isolated from inﬂamed SF by polymer precipitation method and quantiﬁed by Exocet kit and by
nanoparticle tracking analysis. Vesicles expressed all the speciﬁc exosomal markers by immunoblot and FACS. After
isolation with Exoquick, a relevant contamination by immune complexes was detected, which required further magnetic
bead-based puriﬁcation to remove. SF-derived exosomes signiﬁcantly stimulated the release of several inﬂammatory
cytokines and chemokines and metalloproteinases by M1 macrophages but did not inﬂuence the expression of CD80
and CD86 costimulatory molecules. In conclusion, we characterized puriﬁed exosomes isolated from inﬂamed SF and
demonstrate that puriﬁed exosomes are functionally active in their ability to stimulate the release of proinﬂammatory
factors from M1 macrophages. Our data indicate that SF-derived exosomes from gonarthrosis patients play a role in
disease progression.
1. Introduction
Osteoarthritis (OA) is a chronic and progressive musculo-
skeletal disorder that involves the entire synovial joint and
aﬀects patient quality of life. Although multiple pathophysi-
ological mechanisms are involved, the activation of the
innate and immune systems resulting in inﬂammation is a
key component in promoting synovitis as well as progression
of cartilage and bone destruction [1].
Previous studies investigating the inﬂammatory cells
involved in OA reported that macrophages and T lymphocytes
are the most abundant cells, although mast cells and B cells
were also found [2]. Histological studies demonstrated that
synovial macrophages were mostly distributed in the lining
layer and were activated in the inﬂamed joint [3]. Through
the production of proinﬂammatory cytokines, growth
factors, and enzymes, macrophages play a major role in
inﬂammation, including the stimulation of angiogenesis,
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leukocyte and lymphocyte recruitment, ﬁbroblast prolifera-
tion, and protease secretion leading to joint destruction [4, 5].
Exosomes are small membrane-bound extracellular vesi-
cles (EVs) varying in size from 30 to 100 nm originating from
internal budding of the plasma membrane during endocytic
internalization. Exosomes are released from normal and
pathological cells and are present in blood and other bodily
ﬂuids, including malignant ascites, urine, amniotic and syno-
vial ﬂuids, and saliva [6]. The cargo of exosomes (which can
include proteins, messenger and microRNAs, lipids, and
metabolites) reﬂects the biological state of the parent cells
and can be transferred to others cells, acting in a paracrine
or even an endocrine manner to modify the behaviour of
adjacent or distant cells [7].
Recently, it has been proposed that EVs could play a role
in the pathogenesis of numerous inﬂammatory conditions.
EVs (carrying pathogen-associated damage-associated molec-
ular patterns, cytokines, autoantigens, and tissue-degrading
enzyme) create a microenvironment that triggers inﬂamma-
tion and sustains the progression of the disease [8]. Synovial
ﬂuid- (SF-) derived EVs remain poorly characterized to date.
Citrullinated proteins, known to be autoantigens in rheuma-
toid arthritis (RA), were detected in exosomes puriﬁed from
SF of RA patients [9]. Moreover, it has been described that
microvesicles derived from CD4+ T cells, CD19+ B cells,
and CD14+ monocytes are present in OA, RA, and juvenile
idiopathic arthritis SF [10].
Several studies have demonstrated that EVs, produced in
inﬂamed joints, may contribute to disease progression. Exo-
somes released from synovial ﬁbroblasts obtained from RA
patients were found to contain a membrane form of TNFα
that makes activated T cells resistant to apoptosis, favouring
the pathogenic process of RA [11]. In addition, microvesicles
derived from activated monocytes and T cells induce the syn-
thesis of metalloproteinases (MMPs) [12] and cytokines/che-
mokines [13] in RA and OA synovial ﬁbroblasts. In turn,
exosomes from activated synovial ﬁbroblasts induce osteoar-
thritic changes in articular chondrocytes [14].
Despite these earlier ﬁndings, the immune regulatory
properties of the exosomes isolated from inﬂamed SF have
never been investigated. In this study, we characterized SF-
derived exosomes isolated from inﬂamed joints of patients
with gonarthrosis using an integrated system. We compared
two methods of exosome isolation in order to identify the
least contaminated preparation. We then evaluated the
immune regulatory capacity of puriﬁed exosomes on M1
macrophages, since these cells have a key role in the patho-
genesis of OA.
2. Methods
2.1. Isolation of Exosomes from Inﬂamed Synovial Fluid.
Patients scheduled for ﬁrst-intention knee replacement sur-
gery due to end-stage knee osteoarthrosis were recruited at
theOrthopedic Units of theHospital of Udine and of theHos-
pital of Tolmezzo. All patients gave written informed consent.
Inﬂamed synovial ﬂuids (SF) were obtained by needle
aspiration from n = 10 patients (4 males and 6 females, 72
± 8 years). To clarify samples, SF were treated with 2mg/ml
bovine testicular hyaluronidase type I-S (Sigma-Aldrich) for
30 minutes, then centrifuged at 14,000g for 20 minutes,
and supernatants were stored at −80°C until use.
To isolate EVs, SF was incubated with ExoQuick-TC
(System Biosciences) overnight at 4°C and was then centri-
fuged twice at 1500g for 30 and 5 minutes, respectively.
The EV-containing pellet was then resuspended in PBS
buﬀer or lysis buﬀer for subsequent analysis. This technology
works by capturing and collecting EVs in “polymer nets,”
which can be recovered by low-speed centrifugation. Once
the EV-containing pellet is obtained, the supernatant with
the polymer in excess is removed and the EVs can be resus-
pended in a suitable solution, dissolving the polymer net
and releasing intact exosomes [15].
In order to evaluate their immune regulatory properties,
exosomes have been puriﬁed by immunoaﬃnity using Tetra-
spanin Exo-Flow combo capture kit (System Biosciences),
according to the manufacturer’s instructions. Brieﬂy,
streptavidin-conjugated magnetic beads [9.1μm, 1.6 × 107
beads/ml] were coupled with anti-CD9, anti-CD63, and
anti-CD81 biotinylated antibody for 2 h on ice. Afterwards,
exosomes were incubated on a rotating rack at 4°C overnight.
To validate the isolation procedure, exosome-coated beads
were stained on ice for 2 h with Exo-FITC exosome stain
(System BioScience) and then analysed on a FACSCalibur
ﬂow cytometer (BD Biosciences). Finally, exosomes were
eluted from magnetic beads using the elution buﬀer for 2 h
on a rotating rack. Contamination by immune complexes
in isolated exosomes was evaluated by immunoﬁxation
diagnostic assay performed on the fully automated gel elec-
trophoresis instrument InterlabG26 (Interlab).
2.2. Exosome Validation
2.2.1. Quantiﬁcation and Size Proﬁling. The number of
SF-derived exosomes was determined using the Exocet
kit (System Biosciences), according to the manufacturer’s
instructions. The exosomes were lysed using a gentle lysis
solution as to preserve the enzymatic activity of the exosomal
Acetylcholinesterase (AChE) enzyme. A standard curve was
generated using known numbers of exosomes (as measured
by NanoSight) and calibrated with a recombinant AChE
enzyme standard solution provided in the kit.
The number and size of puriﬁed exosomes were deter-
mined by nanoparticle tracking analysis (NTA) equipped
with a 532 nm laser (Nanosight LM10 system, Malvern
Instrument Ltd.) that tracks the particles’ Brownian motion
estimating the particle size and concentration. To do this,
500 μl of an appropriately diluted (1 : 400) exosome-
enriched preparation was used, and for each sample, a 60 s
video was captured at a ﬁxed detection threshold of 16.
Temperature was monitored throughout the measurements.
Vesicle size distribution and an approximate concentration
were obtained from the raw data displayed by the associated
software. The experiments were conducted in triplicate.
2.2.2. Flow Cytometry. One milligram of aldehyde/sulfate
latex beads (4μm, Invitrogen) was incubated with 5μg of
puriﬁed anti-CD63 antibody (BD Pharmingen) under
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agitation overnight at 4°C. SF-derived EVs (1× 1010) were
incubated with 5μg anti-CD63 beads in 100μl PBS for
15min at room temperature; the volume was made up to
300μl and incubated for 2 hours at room temperature on a
rotator. To block free binding sites, EV-coated beads were
incubated for 30 minutes with 200mM glycine. After two
washes in PBS with 0.1% BSA, EV-coated beads were stained
with the primary antibody anti-CD9 Alexa 647 (Serotec),
anti-CD81 FITC (Biolegend), and anti-CD7 PE (Becton
Dickinson) or isotype control (BD Biosciences) and analysed
using a FACSCalibur ﬂow cytometer (BD Biosciences).
Exosomes puriﬁed by immunoaﬃnity Exo-Flow kit
were stained with speciﬁc monoclonal antibodies anti-
CD81 FITC (Biolegend), anti-CD63 FITC (Santa Cruz),
anti-CD9 PE (eBiosciences), anti-CD61 FITC (BD Biosci-
ences), and anti-CD41a FITC (BD Biosciences) and
analysed by ﬂow cytometry.
2.2.3. Immunoblotting. Isolated exosomes were lysed in RIPA
buﬀer (150mM sodium chloride, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50mM Tris, pH8.0) supplemented
with protease inhibitors (Sigma-Aldrich) for 30 minutes on
ice. Immunoglobulins were puriﬁed from preparations of
EVs with IgG Pure Proteome™ protein A magnetic beads
kit (Millipore), according to the manufacturer’s instructions.
The lysate was quantiﬁed by Bradford assay (Bio-Rad
Laboratories), and 25μg of proteins derived from EVs iso-
lated by polymer precipitation, 2μg for exosomes isolated
by immunoaﬃnity, and 5μg of immunoglobulins were
mixed with 4× sample buﬀer (8% SDS, 20% 2-mercaptoetha-
nol, 40% glycerol, 0.008% Bromophenol blue, 0.25M Tris,
pH6.8) and boiled for 10 minutes at 95°C. Proteins were
resolved by SDS-PAGE, transferred to PVDF membranes,
blocked in 5% nonfat powdered milk or BSA in TBS-T
(20mM Tris pH7.5, 150mM NaCl, 0.1% Tween-20), and
stained with the following antihuman antibodies: anti-CD9
(1 : 1000, System BioScience), anti-CD63 (1 : 1000, LS Bio),
anti-CD81 (1 : 500, Abcam), anti-TSG101 (1 : 500, Abcam),
anti-RISC complex (1 : 1000 Abcam), anti-calnexin (1 : 1000
Enzo Life Technologies), and anti-58K (1 : 1000 Genetex).
To visualize binding, horseradish peroxidase-conjugated
secondary antibodies (1 : 1000, Dako) were used (ECL
western blotting substrate, Thermo Scientiﬁc).
2.3. Monocyte Isolation and Diﬀerentiation into M1
Macrophages. Human peripheral blood mononuclear cells
(PBMCs) were isolated from EDTA-uncoagulated blood of
blood donors by Ficoll gradient centrifugation (Millipore).
Monocytes were separated from PBMCs by negative selec-
tion using a human CD14+ cell enrichment kit (StemCell
Technologies) according to the manufacturer’s instructions
and resuspended in RPMI medium supplemented with 10%
heat inactivated fetal bovine serum (FBS), 1% glutamine,
1% pyruvate, 1% nonessential aminoacid, 1% penicillin/
streptomycin, 1% Hepes (all from Euroclone). To remove
the exosomal fraction present in FBS, serum was ultracentri-
fuged for 4 hours at 100,000g. Purity of monocytes was over
95% as judged by staining with anti-CD14 (eBiosciences) and
ﬂow cytometry analysis (FACSCalibur). For macrophage
diﬀerentiation, CD14+ monocytes were seeded in multiwell
plates at 5 × 105/cm2 in complete RPMI medium supple-
mented with 100ng/ml granulocyte macrophage colony-
stimulating factor (GM-CSF, Peprotech) and cultivated for
10 days. Medium was changed completely every 3 days.
2.4. Gene Expression Analysis of M1 Macrophages. M1
macrophages (3× 105 cells) were incubated with 7.5× 109
SF-derived exosomes for 6 h, and RNA was extracted using
the RNeasy Mini kit (Qiagen). Puriﬁed RNA concentrations
were determined spectrophotometrically using a NanoDrop
ND100 spectrophotometer (ThermoScientiﬁc). Complemen-
tary DNA (cDNA) synthesis was performed using the
iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories) accord-
ing to the manufacturer’s protocol. Quantitative real-time
polymerase chain reaction (RT-PCR) was performed using
the Roche LightCycler 480 Real-Time PCR System utilizing
SYBR® Green Master Mix (Bio-Rad Laboratories), following
the manufacturer’s instructions. The primers were designed
from available human sequences using the primer analysis
software Primer3. The sequences of the primers used in this
study are the following:
TNFα: Fw:CCCATGTTGTAGCAAACCCT, Rv:TGAG
GTACAGGCCCTCTGAT;
IL10: Fw:GCGCTGTCATCGATTTCTTCCC, Rv:GTTT
CTCAAGGGGCTGGGTC;
IL6: Fw:ACATCCTCGACGGCATCTCA, Rv:TCACCA
GGCAAGTCTCCTCATT;
IL1β: Fw:TGCCCGTCTTCCTGGGAGGG, Rv:GGCTG
GGGATTGGCCCTG.
GAPDH: Fw:AGTATGACAACAGCCTCAAG, Rv:TCT
AGACGGCAGGTCAGGTCCAC.
The expression level of each gene was assessed as com-
pared to the expression of GAPDH. The ΔΔCt method was
used for analysis of RT-PCR data.
2.5. Analysis of CD80/CD86 Expression Level and Cytokine/
Chemokine/MMP Secretion by M1 Macrophages. M1 macro-
phages (3 × 105) were incubated with 7.5 × 109 SF-derived
exosomes for 24 hours or stimulated with 150 UI/ml IFNγ
(Peprotech) for 12 hours and then with 10ng/ml LPS
(Sigma-Aldrich) for 24 hours. The stimulation with IFNγ/
LPS was used as a positive control for these experiments.
The expression level of the costimulatory molecules CD80
and CD86 was evaluated by ﬂow cytometry using the anti-
CD80 (eBiosciences) and anti-CD86 (eBiosciences) antibod-
ies. Flow cytometry was carried out on the FACSCalibur
(Becton Dickson) and data analysed using Flowing software.
Supernatants were also harvested, centrifuged for 10 minutes
at 14,000g, and cytokine/chemokine and MMP concentra-
tions were quantiﬁed with a magnetic bead-based multiplex
assay (Bio-plex Assay, Bio-Rad Laboratories). To ensure that
cytokines were not previously present in our exosome prepa-
ration as contaminants, their presence was investigated
directly in SF-derived isolated exosomes by magnetic bead-
based multiplex assay.
2.6. Statistical Methods. Data are reported as mean± stan-
dard deviation. Statistical analysis has been performed using
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GraphPad Software (version 4.0c). Data were tested for nor-
mal distribution using the Kolmogorov-Smirnov test. Paired
t-test or Wilcoxon test, as appropriate, was used to compare
continuous variables between two groups. A p value less than
0.05 was considered signiﬁcant.
3. Results
3.1. Characterization of SF-Derived EVs Isolated by the
Polymer Precipitation Method. The concentration of EVs iso-
lated by the polymer precipitation method was determined
either measuring the activity of AChE by Exocet kit or by
using nanoparticle tracking analysis (NTA), and the
two results were compared (Figure 1(a)). The mean con-
centration estimated by NTA was higher (7.6± 3.1× 1011
particles/ml) compared to that measured by Exocet kit
(1.3± 1.4× 1011 EVs/ml). As shown in the representative
report of particle size proﬁling measured by NTA
(Figure 1(b)), the majority of the particles were within
the range size of 100 nm (higher peak), but two other
lower peaks corresponding to microvesicles with larger
sizes were also apparent.
To validate the polymer precipitation method, we
analysed the expression of speciﬁc exosomal markers by
immunoblot analysis. As shown in (Figure 1(c)), the iso-
lated SF-derived EVs expressed the surface tetraspanins
CD9, CD63, CD81, and the internal marker TSG101, indi-
cating the validity of this method to isolate exosomes from
the synovial ﬂuid. Images of the entire immunoblots are
available as Supplementary Figure 1 available online at
https://doi.org/10.1155/2017/4814987. The appearance of
multiple bands is due to the presence of human immuno-
globulins, which coprecipitate with EVs and bound HRP-
conjugated secondary antibodies. In order to conﬁrm the
speciﬁcity of the signals of exosomal markers, we
puriﬁed immunoglobulins from the preparations of EVs
and analysed them together with sample of EVs by immu-
noblotting. The comparison between EVs and IgG blots
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Figure 1: Characterization of SF-derived EVs isolated by Exoquick polymer precipitation. (a) Particle concentration was quantiﬁed
measuring the enzymatic activity of the exosomal AChE enzyme by Exocet kit or tracking the particles’ Brownian motion by Nanosight
NTA. Columns, mean; bars, SD. (b) A representative particle size proﬁling by NTA is shown. (c) SF-derived EVs were lysed, and 25μg of
protein was separated in 15% SDS-PAGE gel under reducing condition. The gel was western blotted onto nitrocellulose membranes and
stained with antibodies recognizing exosomal marker proteins CD9, CD63, CD81, and TSG101. (d) EVs were embedded into 4μm beads
coated with anti-CD63 and then stained with speciﬁc monoclonal antibody for CD7, CD9, and CD81 and analysed by ﬂow cytometry.
The antibodies (green peak) were compared with their appropriate isotype control (red peak). Cytometry histograms are shown as one
representative experiment. The histograms represent the percentages of CD7-, CD9-, and CD81-positive beads. Columns, mean; bars, SD.
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showed the presence of the speciﬁc bands related to the
exosomal markers under investigation.
The expression of CD81 and CD9 was conﬁrmed also by
ﬂow cytometry analysis on exosome-coated CD63 beads
(Figure 1(d)). The majority of CD63+-positive exosomes
expressed CD9 (84.6± 18.8%) and CD81 (87.3± 20.6%).
The antibody for CD7 was used as negative control to vali-
date the speciﬁcity of the assay: the lack of CD7+ exosomes
demonstrates the absence of nonspeciﬁc binding of antibod-
ies to the beads.
3.2. Characterization of SF-Derived Exosomes Isolated by the
Immunoaﬃnity Puriﬁcation Method. It has been demon-
strated that polymer precipitation of exosomes can result in
contamination by protein aggregates that copurify with
nanovesicles [16]; in particular, the biophysical properties
of immune complexes overlap with microvesicles, interfering
with the interpretation of ensuing results [17]. The experi-
mental results described in this manuscript conﬁrmed the
presence of immune complex contamination in puriﬁed
vesicle preparations (Figure 2(a), left panel). Considering
that immune complexes may have important immune regu-
latory activities in functional studies, exosome extracts were
further puriﬁed using immunomagnetic beads. As illustrated
in the right panel of (Figure 2(a)), exosomes puriﬁed by
immunoaﬃnity were not contaminated by immune com-
plexes. Size and concentration of SF-derived exosomes puri-
ﬁed by immunoaﬃnity were then determined by NTA
analysis, and results were compared with data obtained on
exosomes isolated by polymer precipitation method. We
observed that the concentration of the particles puriﬁed by
immunoaﬃnity (1.5± 1.2× 1011 particles/ml) was signiﬁ-
cantly lower compared to the concentration measured on
the same samples puriﬁed by polymer precipitation (7.6
± 3.1× 1011 particles/ml) (Figure 2(b)). As shown in the rep-
resentative report of particle size proﬁling measured by NTA
(Figure 2(c)), all the microparticles were approximately
100nm in size. These data conﬁrmed the presence of non-
exosomal contaminants in exosome samples isolated by
polymer precipitation, which corresponds to the peaks com-
prise within 200 and 300nm in (Figure 1(a)). As expected,
the size distribution of the particles puriﬁed by the immu-
noaﬃnity method (88.01± 25.5 nm, range: 55.5–125.9 nm)
was signiﬁcantly more restricted compared to the particles
puriﬁed by polymer precipitation (144.4± 22.2 nm, range
124–187.9 nm) (Figure 2(d)).
To conﬁrm the integrity of exosomes isolated by immu-
noaﬃnity, we assessed the expression of CD9, CD63, CD81,
and TSG101 by immunoblotting (Figure 2(e)). Images
showing the entire blotted membranes are available as Sup-
plementary materials (see Figure 2). The appearance of mul-
tiple bands is due to the presence of the antibodies (heavy
and light chains) used to capture exosomes. In fact, when
ExoFlow elution buﬀer is used, the exosomes and capture
antibodies are both released from the beads. Therefore, to
conﬁrm the speciﬁcity of the signals of exosomal markers,
we puriﬁed immunoglobulins from exosome preparations
and analysed them by immunoblotting together with the cor-
responding samples of exosomes. The comparison between
exosome and IgG blots showed the presence of bands speciﬁc
for the exosomal markers under investigation.
In order to evaluate the impurities in our exosome prep-
arations, we evaluated the expression of proteins associated
with subcellular compartments, which are supposed to be
absent or underrepresented in exosomes, by immunoblotting
analysis. The expression of calnexin (from endoplasmic retic-
ulum), 58K (from Golgi), and RISC complex (from nucleus)
in SF-derived exosomes was evaluated. The results are
reported in Supplementary material section (Figure 2) and
indicate that no contaminants were present in exosomes
puriﬁed by immunoaﬃnity.
Moreover, exosome isolation was further conﬁrmed by
staining vesicles with ExoFITC, a dye that binds posttransla-
tional modiﬁcations of surface protein (such as glycosyla-
tion). As shown in Figure 2(f), 88.6± 7.2% of the exosomes
bound to the beads reacted with the ExoFITC reagent.
Finally, in order to evaluate whether SF-derived exosomes
were of platelet origin, we analysed the expression of platelet
markers (CD41a and CD61) on the surface of exosomes puri-
ﬁed by ﬂow cytometry. The results (Supplementary Figure 3)
show that exosomes isolated by immunoaﬃnity puriﬁcation
did not express platelet markers, instead expressed CD9,
CD81, and CD63 exosomal markers, as expected.
3.3. Proinﬂammatory Eﬀects of SF-Derived Exosomes on M1
Macrophages. At the transcriptional level, M1 macrophages
stimulated with SF-derived exosomes displayed a signiﬁcant
upregulation of IL-1β expression, while mRNA levels of
other cytokines TNFα, IL10, and IL6 were not changed
(Figure 3(a)).
These results were conﬁrmed at the protein level, since
evaluation of a large panel of proinﬂammatory cytokines by
multiplex technology demonstrated that M1 macrophages
treated with SF-derived exosomes (Figure 3(b)) release sig-
niﬁcant amounts of IL-1β and to a lesser extent IL-16, but
not TNF-α and IL-6. Of note, IL-8 secretion was decreased.
In contrast to the proﬁle of cytokines released in response
to INF-γ/LPS coincubation, SF-derived exosomes stimulate
the release of IL-6 and TNF-α, followed by a much lower
production of IL-1β and IL-8 (Figure 3(c)). IL-10 production
was substantially unaﬀected, conﬁrming the M1 phenotype
of the macrophages.
In a similar manner, SF-derived exosomes induced the
release of several chemokines (CCL8, CCL15, CCL20, and
CXCL1), while downregulating the production of others
(CCL7 in particular; Figures 4(a) and 4(c)). These results dif-
fered signiﬁcantly from those observed after treatment with
IFNγ/LPS, which stimulate the release of a broader spectrum
of chemokines (Figures 4(b) and 4(d)).
Finally, the production of MMPs by M1 macrophages
treated with SF-derived exosomes was also evaluated. Treat-
ment of M1 macrophages with SF-derived exosomes results
in the release of MMP12 and MMP7 and the inhibition of
MMP8 production (Figure 5(a)). In contrast, the incubation
with IFN-γ/LPS stimulated the production of a wide assort-
ment of MMPs (MMP1, MMP2, MMP7, MMP8, MMP10,
and MMP13), but did not aﬀect MMP12 secretion
(Figure 5(b)).
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To ensure that the cytokines measured were not contami-
nants of the exosome preparations themselves, their presence
was investigated directly in SF-derived puriﬁed exosomes.
The results indicate that IL-1β, IL-16, and TNF-α were below
the level of detection in these preparations (data not shown).
It is well known that activated M1 macrophages upregu-
late the expression of CD80 and CD86, which are costimula-
tory molecules involved in T cell activation. Comparison of
stimulation by SF-derived exosomes with control stimulation
demonstrated that in contrast to IFNγ/LPS, SF-derived exo-
some treatment of M1 macrophages did not change signiﬁ-
cantly the expression of these costimulatory molecules
(Figures 6(a) and 6(b)).
4. Discussion
Cell-derived extracellular vesicles (EVs) released in the syno-
vial ﬂuid (SF) of inﬂamed joints of patients with OA and RA
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Figure 2: Characterization of SF-derived exosomes isolated by immunoaﬃnity. (a) SF-derived exosomes isolated by Exoquick polymer
precipitation or immunoaﬃnity magnetic beads were assessed for immune complex contamination by immunoﬁxation. The
immunoﬁxation gel is shown as one representative experiment. The particle concentration (b) and size (d) were quantiﬁed tracking the
particles’ Brownian motion by Nanosight NTA. Columns, mean; bars, SD, ∗signiﬁcant diﬀerence p < 0 05. (c) A representative particle size
proﬁling by NTA is shown. (e) SF-derived exosomes were lysed, and 2μg of protein was separated in 15% SDS-PAGE gel under reducing
condition. The gel was blotted onto nitrocellulose membranes and stained with antibodies against exosomal markers CD9, CD63, CD81,
and TSG101. (f) Exosomes were bound by Exo-Flow beads, stained with Exo-FITC, and analysed by ﬂow cytometry. Histograms of one
representative experiment are shown. Exosome-bound beads (red peak) were compared with beads alone (white peak).
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are suggested to play a signiﬁcant role in disease progres-
sion, triggering and contributing to the propagation of the
inﬂammatory process and participating in tissue degenera-
tion [8, 18]. It has been shown that EVs isolated from
patient SF contain numerous autoantigens implicated in
autoimmune disease [19–21] and can induce the release
of proinﬂammatory cytokines and growth factors from
synoviocytes in vitro [13, 22, 23].
There has been renewed interest in the use of EVs as bio-
markers to monitor physiological and pathological processes.
However, SF-derived EVs remain poorly characterized.
Earlier studies by Skriner et al. [9] utilized electron micros-
copy and proteomic analysis to characterize isolated SF exo-
somes from patients with RA, highlighting the presence of
fundamental RA autoantigens (i.e., citrullinated proteins)
within such vesicles. In our study, we provide the ﬁrst com-
prehensive characterization of SF-derived exosomes isolated
from inﬂamed joints of patients with knee OA.
Towards this goal, two diﬀerent isolation methods (based
on polymer precipitation and immunoaﬃnity) were
compared to identify an optimum means to purify exosomes
from SF for downstream functional and biomarker studies.
Previous studies using isolated exosomes have provided diﬃ-
cult to interpret results, making cross-comparisons between
diﬀerent studies diﬃcult [15, 16]. Although diﬀerential centri-
fugation coupled with ultracentrifugation has been the most
widely adopted method to isolate exosomes, it has also been
suggested that ultracentrifugation can damage isolated vesi-
cles, reducing their quality and thereby potentially impacting
functional studies [16].
Our results demonstrated a discrepancy between the
quantity of polymer-precipitated Exocet-quantiﬁed EVs
and those counted by NTA, leading us to hypothesize the
presence of contamination by other subcellular materials,
such as immune complexes, lipoproteins, and protein aggre-
gates. Further analysis identiﬁed immune complexes and
protein aggregates as signiﬁcant contributors to the contam-
ination in SF ﬂuid-derived EVs [10, 17] which could alter the
validity of downstream functional assays and proteomic/
genomic studies [15, 16, 24]. By incorporating an additional
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Figure 3: SF-derived exosomes stimulate the production of several cytokines by M1 macrophages. (a) M1 macrophages, diﬀerentiated from
normal donor monocytes, were incubated with SF-derived exosomes for 6 hours and cytokine expression was analysed by RT-PCR. Data were
expressed as fold change relative to unstimulated cells. (b) M1 macrophages were treated with SF-derived exosomes (b) or IFN-γ/LPS (c) for
24 hours, and cytokine production was quantiﬁed in supernatants by ELISA Bio-plex cytokine assay system. Data were expressed as fold
change relative to unstimulated cells. Columns, mean; bars, SD, ∗signiﬁcant diﬀerence from unstimulated cells p < 0 05.
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puriﬁcation step utilizing immunoaﬃnity, the EV prepara-
tion was signiﬁcantly enriched in exosomes. As reported for
exosomes isolated from other biological samples (for details
see http://microvesicles.org), we provide the ﬁrst evidence
that SF-derived exosomes express all the speciﬁc exosomal
markers (CD9, CD63, CD81, and TSG101) and can be quan-
tiﬁed through the determination of AchE activity.
Inﬂammation has been considered as the key player pro-
moting synovitis as well as progression of cartilage and bone
destruction in osteoarthritis (OA) [1]. It has been reported
that macrophages become activated in the inﬂamed joint,
where they account for about 30–40% of the cellular content
and regulate secretion of proinﬂammatory cytokines and
enzymes driving the inﬂammatory response [4]. Currently,
several independent groups are attempting to identify and
characterize the factors responsible for the development of
inﬂammatory processes involved in OA. An analysis of the
ever increasing number of reports directs attention to the
special role of the cytokine network in the pathogenesis of
OA, demonstrating that the production of cytokines can vary
depending on the duration and severity of OA [25].
In our study, we investigated the immune regulatory
properties of SF-derived exosomes on proinﬂammatory
M1 macrophages diﬀerentiated from PBMCs of blood
donors. These cells produced a spectrum of anticipated
proinﬂammatory cytokines/chemokines and MMPs in
response to our control stimuli. More importantly, these
cells were activated by SF-derived exosomes to produce
IL-1β and IL-16, supporting our hypothesis that SF-
derived exosomes are able to sustain join inﬂammation
acting on immune cells recruited in the synovium.
The key role of the proinﬂammatory IL-1β in the
pathogenesis of OA is widely recognized. The levels of
IL-1β are generally elevated in OA synovial ﬂuid, indicat-
ing its possible importance in OA pathogenesis and
progression [26] and making it a potential candidate as a
biochemical marker [27, 28]. Importantly, IL-1β is
upstream in the cascade of cytokines involved in OA, since
it induces the expression and release of several other
proinﬂammatory cytokines such as IL-8 and IL-6, as well
as the synthesis of proteases including matrix metallopro-
teinases [29].
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Figure 4: SF-derived exosomes stimulate the production of several chemokines by M1 macrophages. M1 macrophages were treated with SF-
derived exosomes (a–c) or IFN-γ/LPS (b–d) for 24 h, and chemokine production in supernatants was determined by the ELISA Bio-plex
chemokines assay system. Data are displayed as fold change with respect to unstimulated cells. Columns, mean; bars, SD, ∗signiﬁcant
diﬀerence from unstimulated cells p < 0 05.
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Interestingly, the role of IL-16, a proinﬂammatory cyto-
kine with chemotactic activity towards CD4+ T lymphocytes,
monocytes, and eosinophils, has never been thoroughly
investigated. Recently, it has been reported that expression
of IL-16 is decreased during chondrogenesis, whereas a
marked increase was observed during OA progression [30].
In our study, we also observed that SF-derived exosomes
are able to stimulate the production of CCL20, CCL15, and
CXCL1 chemokines by M1 macrophages. Chemokines play
a key role in the perpetuation of inﬂammation by attracting
proinﬂammatory cells to the inﬂamed joint [31]. CCL20
may play an important role in the pathogenesis of OA by
inducing changes in phenotype and catabolic gene expres-
sion in chondrocytes [32]. On the other hand, CXCL1 is
upregulated in OA chondrocytes [33] and its activity is linked
to cartilage development, where it induces chondrocyte
hypertrophy and apoptosis [34, 35].
We also demonstrate that M1 macrophages stimulated
by SF-derived exosomes release MMP12 and MMP7. Degra-
dation of the cartilage extracellular matrix is a central feature
of the OA and is widely thought to be mediated by protein-
ases that degrade structural components of the matrix, pri-
marily aggrecan and collagen; MMPs are the primary
enzymes responsible for the degradation of cartilage [36].
Notably, we observed that SF-derived exosomes, unlike
IFN-γ/LPS, are able to promote the production of MMP12,
suggesting that the vesicles act through a speciﬁc and alterna-
tive pathway compared to that involving LPS recognition
(which are CD14/TLR4 mediated) or IFNγ signalling cas-
cade. A recent study showed that the expression of MMP12
in the cartilage and subchondral bone of patients with OA
correlates with disease severity, consistent with the ﬁndings
described above [37]. On the other hand, a study conducted
by Ohta and colleagues reported that MMP7 is overproduced
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Figure 6: Expression of CD80 and CD86 by M1 macrophages following exposure to SF-derived exosomes. M1 macrophages were
incubated in the presence of IFN-γ/LPS (grey column) or SF-derived exosomes (black column), and the percentage of CD80- (a) and
CD86- (b) positive cells was determined by ﬂow cytometry after 24 hours. Columns, mean; bars, SD. ∗signiﬁcant diﬀerence from
unstimulated cells p < 0 05.
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Figure 5: SF-derived exosomes stimulate the production of several MMPs by M1 macrophages. M1 macrophages were treated with SF-
derived exosomes (a) or IFN-γ/LPS (b) for 24 h, and MMP production was determined in supernatants by the ELISA Bio-plex assay
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in human OA cartilage and may play a signiﬁcant role in the
ECM degradation [38].
Finally, we report that SF-derived exosomes do not
inﬂuence the expression of CD80 and CD86 costimulatory
molecules on M1 macrophages, suggesting that they are not
involved in the activation of T cells through this pathway.
In conclusion, we showed that exosomes isolated from
the SF of inﬂamed joints of patients with OA are able to stim-
ulate M1 macrophages to release key molecules involved in
the inﬂammatory process and cartilage degeneration. Many
studies have dealt with the immunosuppressive properties
of exosomes, especially in oncology, while their proinﬂam-
matory eﬀects are still poorly understood despite the consid-
erable level of interest to better understand the mechanisms
driving chronic inﬂammatory disorders.
Our data suggest that SF-derived exosomes may be key
mediators in OA and could be a useful tool to recreate the
inﬂammatory microenvironment typically associated with
this disease in vitro. Our results provide a better under-
standing of the molecular and cellular mechanisms
involved in the disease pathogenesis of gonarthrosis and lead
the way for the identiﬁcation of new and more eﬀective
therapeutic strategies.
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